We conducted research based on life sciences transactions that closed between 2010 and 2017 to learn whether M&A contributes to shareholder value.
Choose your deal strategy wisely
2018 M&A Firepower Report: Life sciences deals and data
Life sciences deal intentions remain above trend
MDR and IVDR: reshaping Europe’s medtech industry
Looking beyond China to create a global IVD company
The operating room of the future
Medtech innovation for the aging world
Investing in China for the long term
Building value through creative deal structures
Finding sustainability in biotechnology, pharmaceutical and medical technology
Amplified business decisions are the new norm thanks to rapid changes. From new market entrants and regulatory reform to expiring patents and the growing challenge of chronic diseases, leaders in the life sciences community must explore a new course to address the changing climate for health care — one driven by patients and focused on health outcomes.
Our Global Life Sciences Network brings together a worldwide team of professionals to help you achieve your potential.
We cover key issues in these areas:
Connect with us
Stay connected with us through social media, email alerts or webcasts. Or download our EY Insights app for mobile devices.
Pharmaceutical sector news
How will IFRS 10 and IFRS 11 impact collaboration arrangements in the life sciences industry? We explain.